Clinical trial
Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive
NCT03178071
Study timeline
Registry last updated2019-11-04
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Interventions
LorlatinibDRUG · verified · RxNorm: lorlatinib
Sponsors & collaborators
Pfizerlead sponsor
Mapped research locations
ColumbusOhio, United States6BostonMassachusetts, United States4New YorkNew York, United States3DetroitMichigan, United States3ChicagoIllinois, United States2St LouisMissouri, United States2Long BeachCalifornia, United States2OrangeCalifornia, United States2DallasTexas, United States1San FranciscoCalifornia, United States1SeattleWashington, United States1PittsburghPennsylvania, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03178071 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.